SPS block
PreclinicalSmall molecule
SPS block is one of 33 small molecule programs targeting Chronic pain. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
193 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Tramadol Plus Acetaminophen
Johnson & JohnsonPhase 3
Tapentadol ER
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Opana
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Naloxone Hydrochloride
PPurdue Pharma LP
Phase 3
MS Contin
Merck & Co.Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Dayvigo
EisaiPreclinical
Intuniv
PPromius Pharma, LLC
Preclinical
Ultram
Haisco Pharmaceutical Group Co., Ltd.Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SPS block. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMedipol University